Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Moderate Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $20.57.

Several research firms have recently commented on STOK. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 6th. Canaccord Genuity Group cut their price target on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Finally, Wedbush increased their price objective on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th.

Stoke Therapeutics Trading Down 3.4 %

STOK stock opened at $15.07 on Thursday. The company has a market capitalization of $785.45 million, a P/E ratio of -6.25 and a beta of 0.88. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $17.58. The business has a 50 day simple moving average of $13.61 and a 200-day simple moving average of $8.96.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, May 6th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.03. The company had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $3.33 million. Research analysts predict that Stoke Therapeutics will post -2.3 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 5,126 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $13.20, for a total value of $67,663.20. Following the completion of the sale, the general counsel now directly owns 2,598 shares in the company, valued at $34,293.60. The disclosure for this sale can be found here. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. Sherbrooke Park Advisers LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at about $48,000. Corton Capital Inc. acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at about $58,000. Public Employees Retirement System of Ohio acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at about $64,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $141,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.